Project Grant R01DK140954
Award Date
7/1/25
Completion Date
4/30/29
Dollars Obligated
$790K
Similar Awards
This Project Grant award, totaling $233,600.00 and spanning September 1, 2024 to June 30, 2027, was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award supports high-throughput functional analyses of genetic drivers of inflammatory bowel disease (IBD), a debilitating condition characterized by chronic inflammation and erosion of intestinal functions. The...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847) provides $1,255,725 to the Icahn School of Medicine at Mount Sinai to develop manufacturing technologies and advance defined live biotherapeutic products (LBPs) for the treatment of recurrent Clostridioides difficile infection (rCDI) and ulcerative colitis. The key objectives are to: 1) develop a solid-state fermentation platform to enable rapid, scalable manufacturing of defined...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $548,802 to Ancilia Biosciences Inc. to enhance the colonization of the live biotherapeutic product E. coli Nissle 1917 (ECN) using CRISPR-Cas immunity. The goal is to improve ECN's therapeutic efficacy for inflammatory bowel disease (IBD) by protecting it from predatory phages that can limit its...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $673,379 to Rise Therapeutics LLC to develop a novel synthetic biology-based cellular medicine for treating ulcerative colitis. The goal is to create an orally administered immunotherapy that can reduce gut inflammation, improve gastrointestinal mucosal barrier function, and restore the natural microbiome in...
This $919,404 federal Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports the development of QR401, a first-in-class oral nanomedicine targeting antigen-presenting cells (APCs) for the treatment of inflammatory bowel disease (IBD). The funding will enable Qrono, Inc., a for-profit R&D company, to prepare and characterize enteric-coated...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a novel probiotic yeast-based immunotherapy to prevent the transmission of Clostridioides difficile (C. difficile) infections. The $511,553 award to the University of Maryland, Baltimore will fund research to screen for lead bi-specific antibody fragments against the C. difficile surface protein...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $698,074 to Vitakey Inc. to develop a platform technology for targeted oral delivery of therapeutic proteins to the intestines, with a focus on treating ulcerative colitis. The key objectives are to formulate the large protein rhPRG4 to protect it from degradation in the gastrointestinal tract and enable...
This $202,728 federal Project Grant awarded by the National Science Foundation's (NSF) Computer and Information Science and Engineering (CISE) program funds a collaborative research project to develop a theragnostic (therapeutic and diagnostic) system for inflammatory bowel diseases (IBD). The project aims to integrate data science, synthetic biology, and additive manufacturing to model the complex interplay of host, microbial, and environmental factors in IBD, and develop an engineered...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $151,643 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the University of Colorado-Denver. The grant supports research to develop proteolysis targeting chimeras (PROTACs) that can stabilize hypoxia-inducible factors (HIF) to enhance barrier formation and wound healing in inflammatory bowel disease models. The project aims to elucidate the...
This $220,930 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) supports research to investigate the role of the protein myosin 5B in regulating intestinal microvilli assembly and susceptibility to bacterial infection in Crohn's disease. The research aims to elucidate how myosin 5B trafficking of intermicrovillar adhesion complex (IMAC) proteins impacts microvilli...